|  |
| --- |
| **Table 1: Clinical and Demographic Characteristics of the study population grouped according to Zoster exposure status**  |
| **Subject's characteristic** | **Non-HZ group**N = 23,197 | **HZ group**N = 23,197 | **P-value** |
| **Males,** % (n/N) | 35.4 (8,214/23,197) | 35.4 (8,214/23,197) |  |
| **Age at zoster**, yearsMean±SD (n) Median Min; Max | 42.3±20.2 (n=23,197)39.0 0; 88 | 42.4±20.3 (n=23,197)39.0 0; 88 | 0.883 |
| **Diabetes mellitus,** % (n/N) | 16.8 (3,891/23,197) | 16.8 (3,891/23,197) |  |
| **Hypertension,** % (n/N) | 27.1 (6,288/ 23,197) | 27.1 (6,288/ 23,197) |  |
| **Dyslipidemia,** % (n/N) | 6.9 (1,612/23,197) | 7.9 (1,830/23,197) | <0.001 |
| **Prior stroke,** % (n/N) | 0.3 (77/23,197) | 0.3 (70/23,197) | 0.563 |
| **Prior MI,** % (n/N) | 2.0 (474/23,322) | 2.7 (617/23,322) | <0.001 |
| **Smoking,** % (n/N) | 21.5 (2,2676/10,562) | 21.3 (2,109/9,895) | 0.769 |

|  |
| --- |
| **Table 2: Post Zoster vascular event survival** |
| **Parameter** | **Non zoster** | **Zoster** | **P-value** |
| **MACCE,** Survival %\* ± SD (n) | 72.2% ± 0.02 (1,778) | 57.3%± 0.13 (1,988) | <0.001 |
| **Stroke,** Survival %\* ± SD (n) | 95.6% ± 0.01 (319) | 93.1% ± 0.02(364) | 0.068 |
| **Acute MI,** Survival %\* ± SD (n) | 86.5% ± 0.26 (823) | 66.2% ± 0.13 (988) | <0.001 |

|  |
| --- |
| **Table 3: Multivariable Cox regression for HZ exposure on the study outcomes** |
|  |  | Years from exposure to zoster |
|  |  | 1 | 5 | 15 |
| MACCE |  |  |  |
|  | Hazard ratio (95% CI) | 1.21 (1.04; 1.42) | 1.01 (0.99;1.20) | 1.05 (0.96; 1.14) |
|  | P value | 0.016 | 0.089 | 0.280 |
| Stroke |  |  |  |
|  | Hazard ratio (95% CI) | 0.78 (0.50; 1.21) | 1.03 (0.82; 1.30) | 1.12 (0.93; 1.36) |
|  | P value | 0.271 | 0.791 | 0.226 |
| AMI |  |  |  |
|  | Hazard ratio (95% CI) | 1.30 (0.95; 1.78) | 1.07 (0.87; 1.33) | 1.02 (0.85; 1.22) |
|  | P value | 0.098 | 0.486 | 0.867  |

\* Multivariable regression is adjusted to gender, age, diabetes, hypertension, socioeconomic status, dyslipidemia, and prior AMI





**Figure 3: Event-free survival in zoster subjects, by use of antiviral drug one month after exposer to zoster**

|  |
| --- |
| **MACCE** |
| p-value < 0.001 |
| (a)Without Anti-viral treatmentAnti-viral treatment |
|  |
| **Stroke** | **AMI** |
| p-value < 0.001 | p-value <0.001 |
| (b)Anti-viral treatmentWithout Anti-viral treatment | (c)Without Anti-viral treatmentAnti-viral treatment |
| (a) Time to MACCE, (b)Time to stroke , (c) Time to AMI |